Mizuho analyst Steven Valiquette raised the firm’s price target on Cardinal Health (CAH) to $150 from $142 and keeps an Outperform rating on the shares. The firm, which currently expect tariffs to be fairly neutral as Pharma may offset Medical, made no changes to its model for tariffs or for FDA layoffs, but increased EPS estimates for additional expected M&A accretion. The firm increased its FY25 EPS estimate to $8.00 from $7.95, its FY26 estimate to $9.05 from $8.85 and its FY27 forecast to $10.13 from $9.75, the analyst noted.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAH:
- Cardinal Health: Strong Fundamentals and Growth Prospects Justify Buy Rating Despite Tariff Concerns
- Cardinal Health call volume above normal and directionally bullish
- Cardinal Health Appoints New Independent Directors
- Elliott exits Cardinal Health, cuts NRG Energy in Q4
- AMD, Spotify downgraded: Wall Street’s top analyst calls